Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

被引：0

作者：

Relinde I. Y. Lieverse

Evert J. Van Limbergen

Cary J. G. Oberije

Esther G. C. Troost

Sine R. Hadrup

Anne-Marie C. Dingemans

Lizza E. L. Hendriks

Franziska Eckert

Crispin Hiley

Christophe Dooms

Yolande Lievens

Monique C. de Jong

Johan Bussink

Xavier Geets

Vincenzo Valentini

Giuliano Elia

Dario Neri

Charlotte Billiet

Amir Abdollahi

David Pasquier

Pierre Boisselier

Ala Yaromina

Dirk De Ruysscher

Ludwig J. Dubois

Philippe Lambin

机构：

[1] Maastricht University,The D

[2] Maastricht University Medical Center,Lab and The M

[3] Faculty of Medicine and University Hospital Carl Gustav Carus at Technische Universität Dresden,Lab, Department of Precision Medicine, GROW

[4] OncoRay, School for Oncology and Developmental Biology

[5] National Center for Radiation Research in Oncology,Department of Radiation Oncology (MAASTRO), GROW

[6] Technical University of Denmark, School for Oncology and Developmental Biology

[7] Erasmus MC Rotterdam,Department of Radiotherapy and Radiation Oncology

[8] Maastricht University Medical Centre,Department of Health Technology

[9] University Hospital and Medical Faculty Tübingen,Department of Pulmonary Medicine

[10] Eberhard Karls University Tübingen,Department of Pulmonary Diseases, GROW

[11] University College London Cancer Institute, School for Oncology and Developmental Biology

[12] University Hospitals KU Leuven,Department of Radiation Oncology

[13] Ghent University Hospital and Ghent University,Cancer Research UK Lung Cancer Centre of Excellence

[14] Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital,Department of Respiratory Diseases, Respiratory Oncology Unit

[15] Radboud University Medical Center,Department of Radiation Oncology

[16] Cliniques Universitaires Saint-Luc,Department of Radiation Oncology

[17] MIRO - IREC Lab,Department of Radiation Oncology

[18] UCL,Department of Radiation Oncology

[19] Fondazione Policlinico Universitario A. Gemelli IRCCS,Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia

[20] Università Cattolica del Sacro Cuore,Department of Chemistry and Applied Biosciences

[21] Istituto di Radiologia,Department of Radiation Oncology

[22] Philochem AG,University of Antwerp

[23] Institute of Pharmaceutical Sciences,Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology

[24] ETH Zurich,Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT)

[25] Iridium Network,Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO)

[26] Faculty of Medicine and Health Sciences,Academic Department of Radiation Oncology

[27] Campus Drie Eiken,Department of Radiation Oncology, ICM

[28] Building S,Val d’Aurelle

[29] Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD),undefined

[30] Heidelberg Ion-Beam Therapy Center (HIT),undefined

[31] Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ),undefined

[32] German Cancer Consortium (DKTK) Core Center,undefined

[33] Heidelberg University and German Cancer Research Center (DKFZ),undefined

[34] Oscar Lambret Comprehensive Cancer Center,undefined

[35] Université de Montpellier,undefined

来源：

BMC Cancer | / 20卷

关键词：

Immunotherapy; L19-IL2; Anti-PD-L1; Anti-PD-1; Radiotherapy; SABR; Phase 2; NSCLC; Stage IV; Multicentre;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Corbacioglu, Selim
Lode, Holger
Ellinger, Susanne
Zeman, Florian
Suttorp, Meinolf
Escherich, Gabriele
Bochennek, Konrad
Gruhn, Bernd
Lang, Peter
Rohde, Marius
Debatin, Klaus Michael
Steinbach, Daniel
Beilken, Andreas
Ladenstein, Ruth
Spachtholz, Rainer
Heiss, Peter
Hellwig, Dirk
Troeger, Anja
Koller, Michael
Menhart, Karin
Riemenschneider, Markus J.
Zoubaa, Saida
Kietz, Silke
Jakob, Marcus
Sommer, Gunhild
Heise, Tilman
Hundsdoerfer, Patrick
Kuehnle, Ingrid
Dilloo, Dagmar
Schoenberger, Stefan
Schwabe, Georg
von Luettichau, Irene
Graf, Norbert
Schlegel, Paul-Gerhardt
Fruehwald, Michael
Jorch, Norbert
Paulussen, Michael
Schneider, Dominik T.
Metzler, Markus
Leipold, Alfred
Nathrath, Michaela
Imschweiler, Thomas
Christiansen, Holger
Schmid, Irene
Crazzolara, Roman
Niktoreh, Naghmeh
Cario, Gunnar
Faber, Joerg
Demmert, Martin
Babor, Florian
LANCET ONCOLOGY, 2024, 25 (07): : 922 - 932
[42] ANAKINRA PLUS STANDARD OF CARE FOR THE REDUCTION OF HYPERINFLAMMATION AND RESPIRATORY DISTRESS IN PATIENTS WITH SARSCOV-2 INFECTION: A MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 2/3 TRIAL (ANA-COVID-GEAS STUDY)
Fanlo, P.
Gracia Tello, B.
Fonseca, E.
Alvarez Troncoso, J.
Gonzalez, A.
Prieto-Gonzalez, S.
Freire, M.
Argibay, A.
Pallares Ferreres, L.
Todoli, J. A.
Perez Conesa, M.
Bujan Rivas, S.
Ibanez, B.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 57 - 58
[43] Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial
Giralt, Jordi
Trigo, Jose
Nuyts, Sandra
Ozsahin, Mahmut
Skladowski, Krzysztof
Hatoum, Georges
Daisne, Jean-Francois
Yunes Ancona, Alejandro Cesar
Cmelak, Anthony
Mesia, Ricard
Zhang, Alicia
Oliner, Kelly S.
VanderWalde, Ari
LANCET ONCOLOGY, 2015, 16 (02): : 221 - 232
[44] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling, William H. K.
Jittamala, Podjanee
Watson, James A.
Boyd, Simon
Luvira, Viravarn
Siripoon, Tanaya
Ngamprasertchai, Thundon
Batty, Elizabeth M.
Cruz, Cintia
Callery, James J.
Singh, Shivani
Saroj, Manisaree
Kruabkontho, Varaporn
Ngernseng, Thatsanun
Tanglakmankhong, Nuttakan
Tubprasert, Jaruwan
Abdad, Mohammad Yazid
Madmanee, Wanassanan
Kouhathong, Jindarat
Suwannasin, Kanokon
Pagornrat, Watcharee
Piaraksa, Nattaporn
Hanboonkunupakarn, Pongtorn
Hanboonkunupakarn, Borimas
Poovorawan, Kittiyod
Potaporn, Manus
Srisubat, Attasit
Loharjun, Bootsakorn
Taylor, Walter R. J.
Chotivanich, Vasin
Chotivanich, Kesinee
Imwong, Mallika
Pukrittayakamee, Sasithon
Dondorp, Arjen M.
Day, Nicholas P. J.
Teixeira, Mauro M.
Piyaphanee, Watcharapong
Phumratanaprapin, Weerapong
White, Nicholas J.
LANCET INFECTIOUS DISEASES, 2024, 24 (01): : 36 - 45
[45] Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
Morath, Christian
Schmitt, Anita
Schmitt, Michael
Wang, Lei
Kleist, Christian
Opelz, Gerhard
Susal, Caner
Tran, T. Hien
Scherer, Sabine
Schwenger, Vedat
Kemmner, Stephan
Fischereder, Michael
Stangl, Manfred
Hauser, Ingeborg A.
Sommerer, Claudia
Nusshag, Christian
Kaelble, Florian
Speer, Claudius
Benning, Louise
Bischofs, Christian
Sauer, Sandra
Schubert, Maria-Luisa
Kunz, Alexander
Hueckelhoven-Krauss, Angela
Neuber, Brigitte
Mehrabi, Arianeb
Schwab, Constantin
Waldherr, Ruediger
Sander, Anja
Buesch, Christopher
Czock, David
Boehmig, Georg A.
Reiser, Jochen
Roers, Axel
Mueller-Tidow, Carsten
Terness, Peter
Zeier, Martin
Daniel, Volker
Schaier, Matthias
BMJ OPEN, 2022, 12 (11):
[46] Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Amaria, Rodabe N.
Prieto, Peter A.
Tetzlaff, Michael T.
Reuben, Alexandre
Andrews, Miles C.
Ross, Merrick J.
Glitza, Isabella C.
Cormier, Janice
Hwu, Wen-Jen
Tawbi, Hussein A.
Patel, Sapna P.
Lee, Jeffrey E.
Gersbenwaid, Jeffrey E.
Spencer, Christine N.
Gopalakrishnan, Vancheswaran
Bassett, Roland
Simpson, Lauren
Mouton, Rosalind
Hudgens, Courtney W.
Zhao, Li
Zhu, Haifeng
Cooper, Zachary A.
Wani, Khalida
Lazar, Alexander
Hwu, Patrick
Diab, Adi
Wong, Michael K.
McQuade, Jennifer L.
Royal, Richard
Lucci, Anthony
Burton, Elizabeth M.
Reddy, Sangeetha
Sharma, Padmanee
Allison, James
Futreal, Phillip A.
Woodman, Scott E.
Davies, Michael A.
Wargo, Jennifer A.
LANCET ONCOLOGY, 2018, 19 (02): : 181 - 193
[47] Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
Chandiwana, Nomathemba
Kruger, Chelsea
Johnstone, Hilary
Chughlay, Mohamed Farouk
Ju, Chung
Kim, Byungsu
Dineka, Yengiwe
Arbe-Barnes, Sarah
Miller, Robert
Owen, Andrew
Hill, Andrew
Windgassen, Daniel
Abla, Nada
Marrast, Anne Claire
Duparc, Stephan
Venter, Willem Daniel Francois
EBIOMEDICINE, 2022, 86
[48] Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UKTACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Velikova, Galina
Morden, James P.
Haviland, Joanne S.
Emery, Charlotte
Barrett-Lee, Peter
Earl, Helena
Bloomfield, David
Brunt, Adrian Murray
Canney, Peter
Coleman, Robert
Verrill, Mark
Wardley, Andrew
Bertelli, Gianfilippo
Ellis, Paul
Stein, Rob
Bliss, Judith M.
Cameron, David
LANCET ONCOLOGY, 2023, 24 (12): : 1359 - 1374
[49] Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
Fennell, Dean
Griffiths, Daniel
Eminton, Zina
Morgan-Fox, Abigail
Hill, Kayleigh
Ewings, Sean
Stuart, Charlotte
Johnson, Lucy
Mallard, Kim
Nye, Mavis
Darlison, Liz
Dulloo, Sean
Cave, Judith
Luo, Jin-Li
Taylor, Paul
Spicer, Jake
Poile, Charlotte
Bzura, Aleksandra
Griffiths, Gareth
BMJ OPEN, 2023, 13 (11):
[50] Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Vlaar, Alexander P. J.
de Bruin, Sanne
Busch, Matthias
Timmermans, Sjoerd A. M. E. G.
van Zeggeren, Ingeborg E.
Koning, Rutger
ter Horst, Liora
Bulle, Esther B.
van Baarle, Frank E. H. P.
van de Poll, Marcel C. G.
Kemper, E. Marleen
van der Horst, Iwan C. C.
Schultz, Marcus J.
Horn, Janneke
Paulus, Frederique
Bos, Lieuwe D.
Wiersinga, W. Joost
Witzenrath, Martin
Rueckinger, Simon
Pilz, Korinna
Brouwer, Matthijs C.
Guo, Ren-Feng
Heunks, Leo
van Paassen, Pieter
Riedemann, Niels C.
van de Beek, Diederik
LANCET RHEUMATOLOGY, 2020, 2 (12): : E764 - E773

← 1 2 3 4 5 →